Justin Ferdinandus

13PUBLICATIONS
52CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)HaematologyAnimal immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma.

|Feb 09, 2026
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.

Jan-Michel Heger, Julia Mattlener, Helen Kaul

|Oct 11, 2025
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma.

Marie Lommen, Jasmin J Weindler, Janina Jablonski

|Jul 17, 2025
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Justin Ferdinandus, Helen Kaul, Alexander Fosså

|Sep 30, 2024
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.

Jan-Michel Heger, Laman Mammadova, Julia Mattlener

|Sep 21, 2023
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.

Justin Ferdinandus, Lutz van Heek, Katrin Roth

Pageof 3

Frequent Collaborators

5 joint publications

Carsten Kobe

5 joint publications

Bastian von Tresckow

4 joint publications

Paul J Bröckelmann

3 joint publications

Dennis A Eichenauer